Underutilization of evidence-based therapies in heart failure: The pharmacist's role

Pharmacotherapy

Volumn 27, Issue 4 PART 2, 2007, Pages

  Rodgers, Jo Ellen ^a   Stough, Wendy Gattis ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Campbell University   (United States)

Author keywords

Evidence based therapies; Heart failure; Pharmacist's role

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; METOPROLOL; SPIRONOLACTONE; VASOACTIVE AGENT;

ADVERSE OUTCOME; ATTITUDE TO ILLNESS; CLINICAL TRIAL; CONFERENCE PAPER; COST CONTROL; DATA BASE; DEPRESSION; DISEASE EXACERBATION; DRUG COST; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; FATIGUE; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HEART FAILURE; HUMAN; INTERDISCIPLINARY EDUCATION; PATIENT COMPLIANCE; PATIENT COUNSELING; PHARMACIST; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; RESPONSIBILITY; SEXUAL DYSFUNCTION; TEAMWORK; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 34047145455     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.4part2.18S     Document Type: Conference Paper

References (45)

1. DeFrances CJ, Podgornik MD. 2004 National hospital discharge survey. Advance data from vital and health statistics; no 371. Hyattville, MD: National Center for Health Statistics, 2006. Available from www.cdc.gov/nchs/ data/ad/ad.371.pdf. Accessed October 10, 2006.
2. Heart Failure Society of America (HFSA). HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. J Card Fail 2006;12:e1-122.
3. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56-61.
4. LaPointe NM, Kramer JL, Hammil BG, et al. Long-term adherence to evidence-based therapies for coronary artery disease and heart failure in the outpatient setting [abstr]. J Am Coll Cardiol 2002;39:517A.
5. Acute Decompensated Heart Failure National Registry. ADHERE registry benchmark report, September 2004. Available from http://www. adhereregistry.com/index.html. Accessed September 2006.
6. Fonarow GC, Yancy CW, Heywood JT, for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Adherence to heart failure quality-of-care indicators in U.S. hospitals: analysis of the ADHERE registry. Arch Intern Med 2005;165:1469-77.
7. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005;294:1240-7.
8. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol 2004;43:2036-43.
9. Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J 2006;152:454.e1-454. e8.
10. Stafford RS, Davidson SM, Davidson H, Miracle-McMahill H, Crawford SL, Blumenthal D. Chronic disease medication use in managed care and indemnity insurance plans. Health Serv Res 2003;38:595-612.
11. Johnson D, Jin Y, Quan H, Cujec B. β-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. J Am Coll Cardiol 2003;42:1438-45.
12. Lappe JM, Muhlestein JB, Lappe DL, et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med 2004;141:446-53.
13. Lee DS, Mamdani MM, Austin PC, et al. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med 2004;116:581-9.
14. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002;162:1682-8.
15. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ, for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572-80.
16. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004;110:724-31.
17. Ezekowitz J, McAlister FA, Humphries KH, et al, for the APPROACH Investigators. The association among renal insufficiency, pharmacotherapy, and outcomes in 6427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:1587-92.
18. Galvao M, Kalman J, DeMarco T, et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the acute decompensated heart failure national registry (ADHERE). J Card Fail 2006;12:100-7.
19. Galvao M, for the ADHERE Study Group. Reshaping our perception of the typical hospitalized heart failure patient: a gender analysis of data from the ADHERE heart failure registry. J Card Nursing 2005;20:442-50.
20. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, for the ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the acute decompensated heart failure national registry (ADHERE) database. J Am Coll Cardiol 2006;47:76-84.
21. Ahmed A, Roseman JM, Duxbury AS, Allman RM, DeLong JF. Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J 2002;144:365-72.
22. Cowper PA, DeLong ER, Whellan DJ, Allen LaPointe NM, Califf RM. Economic effects of β-blocker therapy in patients with heart failure. Am J Med 2004;116:104-11.
23. Schwartz JS, Wang YR, Cleland JG, Gao L, Weiner M, Poole-Wilson PA, for the ATLAS Study Group. High- versus low-dose angiotensin-converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the assessment of treatment with lisinopril and survival (ATLAS) trial. Am J Manag Care 2003;9:417-24.
24. Smith DG, Cerulli A, Frech FH. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clin Ther 2005;27:951-9.
25. Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the valsartan heart failure trial (Val-HeFT). Am Heart J 2004;148:122-8.
26. Gupta R, Tang WH, Young JB. Patterns of β-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J 2004;147:79-83.
27. Jacob S, Balletshofer B, Henriksen EJ, et al. β-blocking agents in patients with insulin resistance: effects of vasodilating β-blockers. Blood Press 1999;8:261-8.
28. Bakris GL, Fonseca V, Katholi RE, et al, for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-36.
29. Deedwania PC, Giles TD, Klibaner M, et al, for the MERIT-HF Study Group. Efficacy, safety, and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005;149:159-67.
30. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of β-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001;37:1950-6.
31. Tafreshi MJ, Weinacker AB. β-Adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy 1999;19:974-8.
32. Hauf-Zachariou U, Widmann L, Zulsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993;45:95-100.
33. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. β-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. J Am Med Assoc 2002;288:351-7.
34. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Lukas MA, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the IMPACT-HF (initiation management predischarge: process for assessment of carvedilol therapy in heart failure) trial. J Am Coll Cardiol 2004;43:1534-41.
35. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to β-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002;40:1589-95.
36. Fonarow GC, Abraham WT, Albert NM, et al. Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. Am Heart J 2004;148:43-51.
37. Joint Commission on Accreditation of Healthcare Organizations. Heart failure core measure set. February 2006. Available from http://www.jointcommission.org/Performance Measurement. Accessed October 11, 2006.
38. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. J Am Med Assoc 2004;291:1358-67.
39. Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study Investigators. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the pharmacist in heart failure assessment recommendation and monitoring (PHARM) study. Arch Intern Med 1999;159:1939-45.
40. Rainville EC. Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health-Syst Pharm 1999;56:1339-42.
41. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart failure. Br J Clin Pharmacol 2005;60:183-93.
42. Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoes AW, Leufkens HG. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail 2003;9:404-11.
43. Jain A, Mills P, Nunn LM, et al. Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents. Eur J Heart Fail 2005;7:405-10.
44. Clark AM, McMurray JJ, Morrison CE, Murdoch DL, Capewell S, Reid ME. A qualitative study of the contribution of pharmacists to heart failure management in Scotland. Pharm World Sci 2005;27:453-8.
45. Bucci C, Jackevicius C, McFarlane K, Liu P. Pharmacist's contribution in a heart function clinic: patient perception and medication appropriateness. Can J Cardiol 2003;19:391-6.